Skip to main content

Drug Interactions between ivacaftor / tezacaftor and norgestrel

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

norgestrel tezacaftor

Applies to: norgestrel and ivacaftor / tezacaftor

Consumer information for this interaction is not currently available.

MONITOR: Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) or vanzacaftor, tezacaftor, and deutivacaftor may increase the risk for rash events. In one clinical study, the overall incidence of rash events was 10.9% in IVA/TEZ/ELX-treated and 6.5% in placebo-treated patients. The incidence of rash events was 16.3% in females and 5.8% in males for IVA/TEZ/ELX-treated patients and 8.3% in females and 4.8% in males for placebo-treated patients. For IVA/TEZ/ELX-treated patients, the incidence of rash events was 20.5% in females taking a hormonal contraceptive and 13.6% in females not taking a hormonal contraceptive. In other studies, the incidence of rash was 11% in vanzacaftor, tezacaftor, and deutivacaftor treated patients and 7.7% in IVA/TEZ/ELX-treated patients. The incidence of rash was 9.4% in males and 13% in females with vanzacaftor, tezacaftor, and deutivacaftor treatment and 7.6% in males and 7.9% in females with IVA/TEZ/ELX treatment. Rash events were generally mild to moderate in severity with either treatment. The mechanism of this interaction is unknown.

MANAGEMENT: Monitor for rash in patients taking hormonal contraceptives and IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor. Consider interrupting IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor and hormonal contraceptives in patients who develop rash. Once the rash clears, IVA/TEZ/ELX or vanzacaftor, tezacaftor, and deutivacaftor may be restarted without the hormonal contraceptives. If rash does not recur, resumption of hormonal contraceptives can be considered.

Drug and food interactions

Moderate

norgestrel food

Applies to: norgestrel

Grapefruit juice may increase the blood levels of certain medications such as norgestrel. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norgestrel. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.

Moderate

ivacaftor food

Applies to: ivacaftor / tezacaftor

Ivacaftor should be taken with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products to help with its absorption. Do not consume grapefruit juice or any food that contains grapefruit or Seville oranges during treatment with ivacaftor unless directed otherwise by your doctor. Grapefruit juice can significantly increase the blood levels of ivacaftor. This may increase the risk and/or severity of serious side effects such as liver damage. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

tezacaftor food

Applies to: ivacaftor / tezacaftor

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.

ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.

MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.

Minor

norgestrel food

Applies to: norgestrel

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.